OBJECTIVES: We conducted a retrospective analysis of patients with extrapulmonary neuroendocrine carcinomas (EPNECs) to explore the distribution and overall outcomes by different regimens and their primary sites. SETTING: We reviewed the outcomes of one of the largest data sets of patients with extrapulmonary small cell carcinomas (EPSCCs) identified at Allegheny General Hospital located in Pittsburgh, Pennsylvania, USA. PARTICIPANTS: Patients diagnosed with grade 3 EPNECs were retrospectively identified. Primary endpoint and epidemiology: Overall survival (OS) with different treatment regimens was the primary endpoint. Also, epidemiological factors such as risk factors, race, family history of cancer, and associated comorbidities were recorded. RESULTS: OS was 16 months in seven patients who received cisplatin/etoposide chemotherapy and 8.5 months in seven patients with carboplatin/etoposide chemotherapy. The commonest primary site was the gastrointestinal tract (GIT). Smoking history association was observed to be 50%. Merkel cell carcinoma (MCC) patients had significantly better OS. Simultaneously, an extensive form of disease pattern was also noticed in 94.4% of the patients. Significantly, neutropenic sepsis was observed in 71.4% of the patients who were treated with cisplatin/etoposide combination. CONCLUSION: EPNECs demonstrated a low response rate to chemotherapy and high rates of distant metastases. Conclusively, brain metastases were rare.
OBJECTIVES: We conducted a retrospective analysis of patients with extrapulmonary neuroendocrine carcinomas (EPNECs) to explore the distribution and overall outcomes by different regimens and their primary sites. SETTING: We reviewed the outcomes of one of the largest data sets of patients with extrapulmonary small cell carcinomas (EPSCCs) identified at Allegheny General Hospital located in Pittsburgh, Pennsylvania, USA. PARTICIPANTS: Patients diagnosed with grade 3 EPNECs were retrospectively identified. Primary endpoint and epidemiology: Overall survival (OS) with different treatment regimens was the primary endpoint. Also, epidemiological factors such as risk factors, race, family history of cancer, and associated comorbidities were recorded. RESULTS: OS was 16 months in seven patients who received cisplatin/etoposide chemotherapy and 8.5 months in seven patients with carboplatin/etoposide chemotherapy. The commonest primary site was the gastrointestinal tract (GIT). Smoking history association was observed to be 50%. Merkel cell carcinoma (MCC) patients had significantly better OS. Simultaneously, an extensive form of disease pattern was also noticed in 94.4% of the patients. Significantly, neutropenic sepsis was observed in 71.4% of the patients who were treated with cisplatin/etoposide combination. CONCLUSION: EPNECs demonstrated a low response rate to chemotherapy and high rates of distant metastases. Conclusively, brain metastases were rare.
Authors: Luis Paz-Ares; Mikhail Dvorkin; Yuanbin Chen; Niels Reinmuth; Katsuyuki Hotta; Dmytro Trukhin; Galina Statsenko; Maximilian J Hochmair; Mustafa Özgüroğlu; Jun Ho Ji; Oleksandr Voitko; Artem Poltoratskiy; Santiago Ponce; Francesco Verderame; Libor Havel; Igor Bondarenko; Andrzej Kazarnowicz; György Losonczy; Nikolay V Conev; Jon Armstrong; Natalie Byrne; Norah Shire; Haiyi Jiang; Jonathan W Goldman Journal: Lancet Date: 2019-10-04 Impact factor: 79.321
Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: Leora Horn; Aaron S Mansfield; Aleksandra Szczęsna; Libor Havel; Maciej Krzakowski; Maximilian J Hochmair; Florian Huemer; György Losonczy; Melissa L Johnson; Makoto Nishio; Martin Reck; Tony Mok; Sivuonthanh Lam; David S Shames; Juan Liu; Beiying Ding; Ariel Lopez-Chavez; Fairooz Kabbinavar; Wei Lin; Alan Sandler; Stephen V Liu Journal: N Engl J Med Date: 2018-09-25 Impact factor: 91.245
Authors: Paul T Nghiem; Shailender Bhatia; Evan J Lipson; Ragini R Kudchadkar; Natalie J Miller; Lakshmanan Annamalai; Sneha Berry; Elliot K Chartash; Adil Daud; Steven P Fling; Philip A Friedlander; Harriet M Kluger; Holbrook E Kohrt; Lisa Lundgren; Kim Margolin; Alan Mitchell; Thomas Olencki; Drew M Pardoll; Sunil A Reddy; Erica M Shantha; William H Sharfman; Elad Sharon; Lynn R Shemanski; Michi M Shinohara; Joel C Sunshine; Janis M Taube; John A Thompson; Steven M Townson; Jennifer H Yearley; Suzanne L Topalian; Martin A Cheever Journal: N Engl J Med Date: 2016-04-19 Impact factor: 91.245
Authors: Jung Han Kim; Se-Hoon Lee; Jinny Park; Ho Young Kim; Soon Il Lee; Eun Mi Nam; Joon-Oh Park; Kihyun Kim; Chul Won Jung; Young-Hyuck Im; Won Ki Kang; Mark H Lee; Keunchil Park Journal: Jpn J Clin Oncol Date: 2004-05 Impact factor: 3.019
Authors: Ingrid Holst Olsen; Ulrich Knigge; Birgitte Federspiel; Carsten Palnæs Hansen; Anna Skov; Andreas Kjær; Seppo W Langer Journal: J Cancer Date: 2014-08-01 Impact factor: 4.207